share_log

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)

Arcutis Biotherapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
美股SEC公告 ·  11/13 16:37

Moomoo AI 已提取核心訊息

Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G/A with the SEC, indicating a shared voting and dispositive power over 10,966,672 shares of Arcutis Biotherapeutics, Inc. common stock, representing 9.38% of the company. The filing, dated September 30, 2024, reflects the holdings as of August 9, 2024, based on the total number of shares outstanding reported in Arcutis Biotherapeutics' Quarterly Report. Rubric Capital Management LP, as an investment adviser, and David Rosen, as Managing Member of the general partner of Rubric Capital, have made this filing in accordance with SEC rules, specifically Rule 13d-1(b). The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G/A with the SEC, indicating a shared voting and dispositive power over 10,966,672 shares of Arcutis Biotherapeutics, Inc. common stock, representing 9.38% of the company. The filing, dated September 30, 2024, reflects the holdings as of August 9, 2024, based on the total number of shares outstanding reported in Arcutis Biotherapeutics' Quarterly Report. Rubric Capital Management LP, as an investment adviser, and David Rosen, as Managing Member of the general partner of Rubric Capital, have made this filing in accordance with SEC rules, specifically Rule 13d-1(b). The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Rubric Capital Management LP 和 David Rosen 已向美國證券交易委員會(SEC)提交了一份修正後的13G/A表格,表示他們共同擁有對10,966,672股arcutis biotherapeutics, Inc.普通股的投票權和處置權,代表公司9.38%的股份。該文件日期爲2024年9月30日,反映截至2024年8月9日的持股情況,基於在arcutis biotherapeutics的季度報告中報告的總流通股數。作爲投資顧問的Rubric Capital Management LP,以及作爲Rubric Capital普通合夥人管理成員的David Rosen,按照SEC規則,特別是第13d-1(b)條款,提交了此文件。該文件聲明,所持股份是在正常業務過程中獲得的,而非爲了改變或影響發行人的控制權而獲取的。
Rubric Capital Management LP 和 David Rosen 已向美國證券交易委員會(SEC)提交了一份修正後的13G/A表格,表示他們共同擁有對10,966,672股arcutis biotherapeutics, Inc.普通股的投票權和處置權,代表公司9.38%的股份。該文件日期爲2024年9月30日,反映截至2024年8月9日的持股情況,基於在arcutis biotherapeutics的季度報告中報告的總流通股數。作爲投資顧問的Rubric Capital Management LP,以及作爲Rubric Capital普通合夥人管理成員的David Rosen,按照SEC規則,特別是第13d-1(b)條款,提交了此文件。該文件聲明,所持股份是在正常業務過程中獲得的,而非爲了改變或影響發行人的控制權而獲取的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息